High-risk diabetic nephropathy patients: The outcome of evidence-based clinical practice in an outpatient clinic

Diabetes Research and Clinical Practice

Volumn 92, Issue 3, 2011, Pages 356-360

  Slade, Helen ^a   Williams, Sheila M ^a   Manning, Patrick J ^a   Walker, Robert J ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Diabetic nephropathy; Evidence based clinical practise

Indexed keywords

ACETYLSALICYLIC ACID; ALBUMIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CALCITRIOL; CALCIUM; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN;

ADOLESCENT; ADULT; ALBUMIN BLOOD LEVEL; ANEMIA; ARTICLE; BLOOD PRESSURE MEASUREMENT; CHILD; CLINICAL ARTICLE; CLINICAL PRACTICE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DISEASE COURSE; EVIDENCE BASED PRACTICE; FEMALE; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MALE; MEDICAL AUDIT; MICROALBUMINURIA; MICROVASCULARIZATION; OUTPATIENT CARE; PROTEINURIA; RETROSPECTIVE STUDY; SCHOOL CHILD;

ADULT; AGED; AMBULATORY CARE FACILITIES; CREATININE; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MALE; MIDDLE AGED; PROTEINURIA; TREATMENT OUTCOME;

EID: 79957984561     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2011.02.022     Document Type: Article

References (17)

1. Diabetes New Zealand Home Page 2008 [cited 28/03/10]; Available from: http://www.diabetes.org.nz/.
2. Tobias M. Diabetes in New Zealand: models and forecasts 1996-2011 2002, Ministry of Health New Zealand.
3. Hovind P., Rossing P., Tarnow L., Smidt U., Parving H. Progression of diabetic nephropathy. Kidney Int 2001, 59:702-709.
4. Fioretto P., Solini P. Antihypertensive treatment and multifactorial approach for renal protection in diabetes. J Am Soc Nephrol 2005, 16. (Suppl 1):S18-21.
5. Endre Z.H., Beaven D., Buttimore A. Preventable kidney failure: the cost of diabetes neglect?. N Z Med J 2006, 119(1246):U2338.
6. Adler A.I., Stevens R.J., Manley S.E., Bilous R.W., Cull C.A., Holman R.H., et al. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003, 63:225-232.
7. Gaede P., Lund-Andersen H., Parving H.-H., Pedersen O. Effect of a mutifactorial intervention on mortality in type 2 diabetes. N Eng J Med 2008, 358:580-591.
8. Levin A., Rocco M. KDOQI clinical practise recommendations for diabetes and chronic kidney disease. Am J Kid Dis 2007, 49. (Suppl 2):S12-154.
9. Patel M., Shilliday I.R., McKay G.A. A combined diabetes renal clinic improves risk factor management and progression of renal disease in a district general hospital. J Eval Clin Pract 2009, 15:832-835.
10. Jayapaul M.K., Messersmith R., Bennet-Jones D.N., Mead P.A., Large D.M. The joint diabetic-renal clinic in clinical practice: 10years of data from a District General Hospital. QJM 2006, 99:153-160.
11. Chan J.C., So W.-Y., Yeung C.-Y., Ko G., Lau I.T., Tsang M.-W., et al. Effects of structured versus usual care on renal endpoints in type 2 diabetes: the SURE study. Diabetes Care 2009, 32:977-982.
12. Lambers Heerspink H.J., Gansevoort R.T., Brenner B.M., Cooper M.E., Parving H.H., Shahinfar S., et al. Comparison off different measures of urinary protein excretion for prediction of renal events. J Am Soc Nephrol 2010, 21:1355-1360.
13. Cookcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-34.
14. Holman R.R., Paul S.K., Bethel M.A., Neil H.A.W., Matthews D.R. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Eng J Med 2008, 359:1565-1576.
15. Lewis E.J., Hunsicker L.G., Clarke W.R., Berl T., Pohl M.A., Lewis J.B., et al. Collaborative study group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Eng J Med 2001, 345:851-860.
16. Lewis E.J., Hunsicker L.G., Bain R.P., Rohde R.D. The Collaborative study group. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Eng J Med 1993, 329:1456-1462.
17. Morgensen C.E., Neldon S., Tikkanen I., Oren S., Viskoper R., Watts R.W., Cooper M.E. A randomised controlled trial of dual blockade of renin angiotensin system in patients with hypertension, microalbuminuria and non-insulin dependent diabetes. The candersarten and lisinopril microalbuminuria (CALM) study. Br Med J 2000, 321:1440-1444.